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Nanotechnology has transformed materials engineering. However, despite much excitement in 
the scientific community, translation of nanotechnology-based developments has suffered from 
significant translational gaps, particularly in the field of biomedicine [1]. Of the many concepts 
investigated, very few have entered routine clinical application. Safety concerns and associated 
socioeconomic uncertainties, together with the lack of incentives for technology transfer, are 
undoubtedly imposing significant hurdles to effective clinical translation of potentially game-
changing developments. Commercialization aspects are only rarely considered in the early 
stages and in many cases, the market is not identified early on in the process, hence precluding 
market-oriented development. However, methodologies and in-depth understanding of 
mechanistic processes existing in the environmental, health and safety (EHS) community could 
be leveraged to accelerate translation. Here, we discuss the most important stepping stones for 
(nano)medicine development along with a number of suggestions to facilitate future translation. 
The number of new nanotechnology-enabled approaches to solve unmet medical needs is vast 
with numerous proof-of-concept studies completed successfully and many more under way. Many of 
these attempts, irrespective of how clever and effective they are, unfortunately finish with the 
publication of the paper, inevitably resulting in the academic pressure to return to the bench to 
establish preclinical proof of concept once again with an entirely new material. Most academic 
researchers are evaluated based on published papers and third party funding, but not on successful 
technology transfer. As such, it is frequently unappealing to invest time into translating research 
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findings, which is excacerbated by the need for academics to step outside of their comfort zone to 
assume a viewpoint encompassing clinical, regulartory and market aspects.  
Additionally, there is a need to develop methodologies that enable a more holistic 
understanding of the field, and particle biology interactions in particular, which can then be fed into 
risk/benefit models to evaluate whether a nanotechnology-enabled solution outperforms other 
approaches. The number of publications focussing on nanoparticle toxicology and side effects has 
risen exponentially in recent years as the result of many drivers, and not necessarily because of overt 
new hazards but also because of significant public research funding. While such studies should 
specifically focus on product-associated risks in order to bring immediate value to product 
development, the nanomedicine community can benefit tremendously from methods developed 
previously by the EHS community. Studies comparing biological effects of different nanomaterials 
could contribute to a more comprehensive understanding of particle interactions with biological 
entities, which could then be used for a safe design of nanomaterials. Over the past decades, massive 
amounts of data have been collected. However, the interconnections of these data points is mostly 
lacking, which limits holistic understanding. One reason for this is the nature of nanomaterials 
themselves; in contrast to small molecule drugs, they cannot be easily characterized down to atomic 
level. For classical small molecule drugs, the atomic connectivity is clearly defined by the 
International Union of Pure and Applied Chemistry (IUPAC) who have developed a universal 
nomenclature that allows bijective identification of a compound and thus harmonization and 
classification of data points. When moving to nano-drugs however, this cannot be easily accomplished 
and requires detailed understanding of the nanomaterials as well as the pharmacophore. Even though 
major advances have been achieved in the physicochemical characterization of nanostructures, we are 
far away from a bijective identification of nanomaterials. Batch-to-batch variability, compounded by 
lab-to-lab variability, are of significant magnitude and demonstration of equivalency becomes critical 
[2]. Standard procedures cannot be readily translated to nanomaterial evaluation due to the distinctly 
different physicochemical characteristics of particles as opposed to small molecules or bulk materials 
[3], leading to assay interference and skewed data. Hence, a modular set of sound methodologies to 
assess nano-drug properties and biological effects is needed.  
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Appropriate physical, chemical and  biological (in vitro and in vivo) characterisation requires 
a large panel of analytical techniques run by experienced personel. Before the establishment of the 
National Cancer Institute Nanotechnology Characterization Laboratory (NCI-NCL, ncl.cancer.gov) in 
the US in 2005, the sponsors had little choice other than to assemble a panel of experts in 
physicochemical characterization, sterility, microscopy, immunotoxicity, etc, at great effort and 
expense. To date, NCI-NCL is the first and by far most advanced center performing the analytical 
cascade required by the Food and Drug Administration (FDA) according to standards defined in 
cooperation with the National Institute of Standards and Technology (NIST). This facility was unique 
until 2015 when the European Nanomedicine Characterisation Laboratory (EU-NCL, www.euncl.eu), 
was founded by the European Commission under its Horizon 2020 Infrastructure programme. NCI-
NCL and EU-NCL cooperate very closely to harmonize assay cascades and data comparisions. 
Having two large infrastructures linked by a strong transatlantic cooperation, in addition to access to 
GMP production facilities, constitutes an initial step towards a global open market for nanomedicines. 
In addition, systems to globally analyse data along with its quality and completeness need to 
be established [4]. Such systems work remarkably well for areas that can be described sufficiently 
well by a nomenclature that is built on bijective building blocks (such as atoms in small molecule 
drugs, amino acid sequences in proteins or base sequences in genomic data). These building blocks 
and their connectivity must define the identity of the specimen in a bijective manner. This is 
intrinsically challenging for more complex systems, especially when they consist of multiple phases 
(e.g., polymeric, inorganic, lipid, drug etc) and/or are highly susceptible to environmental changes [5, 
6]. The challenge is to find a level of minimal characterisation that describes the system sufficiently 
well to enable retrospective confirmation and prediction of responses under different conditions, 
which can then be validated experimentally [7]. A landmark study by the NCI-NCL spearheaded by 
McNeil and colleagues has recently attempted to quantify major nanomaterial characteristics and 
correlate them with relative benignity. This data can then be fed into a searchable database of 
nanoparticle charateristics and could be of use for ab initio designed nanoparticles in both an EHS and 
nanomedicine context. This has obvious benefits for researchers developing new, engineered, 
nanoparticles, and may enable a “safety by design” approach where developers may learn from 
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exisiting research. A number of efforts are under way to create resources for developers in the field 
[8]. One example of an established database is the DaNa project Knowledge Base Nanomaterials, 
which was founded in 2009 (www.nanoobjects.info) and provides information about the use of 
environmental, health and safety (EHS) data of around 25 industrially relevant nanomaterials and 
their recpective applications. Such databases may provide a framework for rational approaches to 
research and development and generation of hypotheses for further exploration, however, it is 
important that innovation so that an evolving diversity of materials continue to emerge. 
More robust characterisation methods and databases to explore particle-biological interactions 
may also enable a framework to be developed for nanomaterial pharmacokinetics and distribution. 
Nanomaterial exposure may occur via a number of different routes (e.g. oral, parenteral, topical or 
inhaled) and there are different considerations for each. Notwithstanding, oral delivery of 
conventional small molecule drugs presents an excellent example of how molecular descriptors can be 
extremely useful in lead selection through the application of Lipinski’s rule of 5 or its various 
evolutions [9]. In the past 3 decades, physiologically-based pharmacokinetic (PBPK) modelling has 
proliferated for conventional small molecules and is now almost routinely used in development and 
post-licensing environments [10]. PBPK modelling requires a thorough understanding of the precise 
mechanisms that underpin absorption, distribution, metabolism and elimination (ADME) as well as 
the necessary in vitro ADME tools to provide robust and translatable readouts. As such data continues 
to emerge, PBPK modelling may become an increasingly valuable tool in the development of 
nanomedicine-based formulations and will accelerate preclinical development. While such databases 
and modelling may aid the design of safe nanomedicines, experimental demonstration will still be 
imperative in the industrial development process. 
Among the nanomedicine-based products which have successfully been commercialized, the 
majority are based on platform technologies, such as the most mature liposome technology. The other 
marketed nanomedicines are based on polymeric nanostructures, and on iron oxide nanoparticles [11-
13]. Most recently, the field has transitioned to more exotic materials, and nanomedicines based on 
HfO2 (NBTXR3, Nanobiotix) have been submitted for market approval.[12] However, the biggest 
hurdle in translating nanomedicines remains to be commercialization. Developing a nano-based drug 
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requires academics to step out their comfort zone and to take considerable financial risks, which 
imposes a double disincentive to entrepreneurs. Close collaboration between academia, industry, 
governmental institutions and the regulatory agencies, transfer of methodological know-how from the 
EHS community and identification of promising, developable nanomedicines is thus essential for 
successful future translation so that the benefits can ultimately be realised for patients. 
 
 
Figure 1: Nanomedicine suffers from a significant translational gap; only very few nanomedicines 
are successfully translated into clinics.  Standardized assay cascades adapted to nanomedicines, 
searchable databases in combination with modelling data for amore rational lead selection and 
identification of relevant preclinical models may contribute to accelerated translation. Close 
collaboration of academia with industry and clinical partners, and consideration of clinical, 
regulatory and market aspects are imperative for better translation.  JU
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